Marl, Germany

Robert Franke

This inventor holds 162 USPTO granted patents and 82 published patent applications, plus 27 CIPO patents and 197 EPO patents, primarily in Catalyst Development (CPC class B01J2231-321). Top assignees: Evonik Degussa Gmbh, Evonik Operations Gmbh, Evonik Oxeno Gmbh & Co. Kg. Active years: 2013-2026.

USPTO Granted Patents = 162 

% Patents Active = 72.2

 

 

Average Co-Inventor Count = 5.0

ph-index = 10

Forward Citations = 366(Granted Patents)

Forward Citations (Not Self Cited) = 103(Dec 10, 2025)


Inventors with similar research interests:

🔬 See more inventors

Company Filing History:


Years Active: 2013-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Oligomerization Catalyst
Hydroformylation
Alkoxycarbonylation
Platinum Complexes
Diphosphine Ligands
Nanofiltration
Hydrogenation
Ferrocene Ligands
Thermal Separation
Catalyst Regeneration
Aldehydes
Benzene-Based Ligands
162 patents (USPTO):Explore Patents

Title: Robert Franke: A Prolific Inventor in Marl

Introduction:

In the world of inventions and patents, Marl-based inventor Robert Franke has made a significant mark with his remarkable contributions. With an outstanding number of 135 patents to his name, Franke's innovative prowess and commitment to advancing technology have earned him widespread recognition. This article delves into Franke's latest patents, career highlights, notable collaborations, and his overall impact in the field of innovations.

Latest Patents:

Franke's recent patents include groundbreaking developments that demonstrate his expertise in various domains. Two of his notable patents are:

1. "Bisphosphite ligands based on benzopinacol with an open outer unit - Bisphosphite ligands based on benzopinacol with an open outer unit, and the use thereof in hydroformylation."

This patent reveals Franke's exploration of bisphosphite ligands, their structure, and application in hydroformylation processes. Franke's innovation in this area has the potential to pave the way for more efficient and sustainable chemical processes.

2. "Process for hydroformylation of olefins using Pt and iodine or bromine - Process for hydroformylation of olefins using Pt and iodine or bromine."

This patent showcases Franke's expertise in developing a novel process for hydroformylation that utilizes platinum (Pt) combined with iodine or bromine. These findings have implications for the advancement of industrial catalytic processes, contributing to the broader field of chemical engineering.

Career Highlights:

Throughout his career, Robert Franke has thrived in research and development roles within renowned companies. Notably, he has worked with both Evonik Degussa GmbH and Evonik Operations GmbH, where he actively contributed to their innovation pipelines. His extensive experience working with these renowned organizations has further fueled his drive for exploring new frontiers.

Collaborations:

Franke's inventive journey has been enriched by collaborations with like-minded professionals. Two notable coworkers with whom he has collaborated are Dirk Fridag and Katrin Marie Dyballa. These individuals have played instrumental roles in bringing Franke's ideas to life, contributing to the success of various projects and patent applications.

Conclusion:

Robert Franke's impressive portfolio of 135 patents highlights his dedication to pushing the boundaries of innovation. His recent patents in bisphosphite ligands and hydroformylation processes exemplify his versatility and expertise in different domains. Through his extensive career with Evonik Degussa GmbH and Evonik Operations GmbH, Franke has made substantial contributions to the companies' research and development efforts. Collaborations with key individuals like Dirk Fridag and Katrin Marie Dyballa have further amplified the impact of his inventions. In the realm of inventions and patents, Robert Franke's work continues to inspire and shape the future of technology in Marl and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…